Skip to main content

Published locations for 14% of ASCVD patients need a PCSK9 inhibitor to reach LDL goal

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. 14% of ASCVD patients need a PCSK9 inhibitor to reach LDL goal

User login

  • Reset your password
  • /content/14-ascvd-patients-need-pcsk9-inhibitor-reach-ldl-goal
  • /familypracticenews/article/117148/lipid-disorders/14-ascvd-patients-need-pcsk9-inhibitor-reach-ldl
  • /internalmedicinenews/article/117148/lipid-disorders/14-ascvd-patients-need-pcsk9-inhibitor-reach-ldl
  • /clinicalendocrinologynews/article/117148/lipid-disorders/14-ascvd-patients-need-pcsk9-inhibitor
  • /ecardiologynews/article/117148/lipid-disorders/14-ascvd-patients-need-pcsk9-inhibitor-reach-ldl-goal
  • /cardiology/article/117148/lipid-disorders/14-ascvd-patients-need-pcsk9-inhibitor-reach-ldl-goal
  • /endocrinology/article/117148/lipid-disorders/14-ascvd-patients-need-pcsk9-inhibitor-reach-ldl-goal
  • /internalmedicine/article/117148/lipid-disorders/14-ascvd-patients-need-pcsk9-inhibitor-reach-ldl
  • /neurology/article/117148/lipid-disorders/14-ascvd-patients-need-pcsk9-inhibitor-reach-ldl-goal
  • /familymedicine/article/117148/lipid-disorders/14-ascvd-patients-need-pcsk9-inhibitor-reach-ldl-goal
  • /clinicalneurologynews/article/117148/lipid-disorders/14-ascvd-patients-need-pcsk9-inhibitor-reach